Bafna Pharmaceuticals Ltd (BAFNAPH) is currently trading at 302.40 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.

Bafna Pharmaceuticals Limited is engaged in manufacturing pharmaceutical formulations of Betalactum and Non Betalactum products. It operates multiple manufacturing units with WHO GMP and ISO 9000 certifications. The company holds Export House status from the Government of India and has expanded into regulated markets of Europe, exporting products to Srilanka, Ukraine, and Ghana. Bafna Pharmaceuticals has recently set up UK-MHRA & TGA-Australia accredited manufacturing facilities in Chennai, enhancing its capacity to meet export demands. The company has diversified its brand portfolio with the launch of products like Raricap, BSF, Molev, and Lopih targeted towards women's wellness segments.

Over the past 52 weeks, Bafna Pharmaceuticals Ltd has traded between a low of ₹95.00 and a high of ₹318.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.

Bafna Pharmaceuticals Ltd has a market capitalization of approximately 729.92. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.

Bafna Pharmaceuticals Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 93.70 and operates in the its sector sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.

Based on its market capitalization of 729.92 Cr, Bafna Pharmaceuticals Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.

Bafna Pharmaceuticals Ltd operates in the its sector sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.

The Price-to-Earnings (PE) ratio of Bafna Pharmaceuticals Ltd is 93.70. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.